EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
Clinical trial NCT04892472 · TERMINATED
Trial details
- NCT number
- NCT04892472
- Sponsor
- NovoCure GmbH
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-12
- Primary completion
- 2025-01-10
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.